Maria Carmela Piccirillo

Author

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"ORCID

Also Known As

Francesco Perrone, G Nasti, Laurenzia Ferraris, M C Piccirillo, M Leongito, M Piccirillo, M. C. Piccirillo, M. Piccirillo, M.C. Piccirillo, Maria C. Piccirillo

197

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"University of Campania "Luigi Vanvitelli"Istituti di Ricovero e Cura a Carattere Scientifico Fondazione IRCCS Istituto Nazionale dei Tumori Azienda Ospedaliera S.Giuseppe Moscati

About

Maria Carmela Piccirillo is an author at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	29	1.7K
2	Health Sciences	12	12	552
3	Nursing	1	1	23
4	Public Health	1	1	23
5	Endocrinology	1	1	80

Maria Carmela Piccirillo

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl, Journal of Clinical Oncology	2015	478
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, The Lancet Oncology Advanced Ovarian CancerMedicineMetronomic TherapyGynecologyWeek Versus	2014	386
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo, Journal of Clinical Oncology	2012	232
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients Uwe Wagner, Christian Marth, R. Largillier, British Journal of Cancer	2012	182
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial Sandro Pignata, Domenica Lorusso, Giovanni Scambia, The Lancet Oncology Mito 11MedicineMetronomic TherapyGynecologyWeekly Paclitaxel	2015	170
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy Francesco Perrone, Claudio Jommi, Massimo Di Maïo, Annals of Oncology Family MedicineHealth PolicyHealth EconomicsMedicineEpidemiology Of Cancer	2016	149
Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results Vincenza Granata, Roberta Fusco, Maria Carmela Piccirillo, International Journal of Surgery	2015	93
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study Sandro Pignata, Giovanni Scambia, Alessandra Bologna, Journal of Clinical Oncology Gcig StudyCancer ManagementClinical EndpointGynecologyPharmacotherapy	2017	88
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, The Lancet Oncology Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast Cancer	2018	86
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial Quincy S. Chu, Laurent Greillier, Wei Tu, The Lancet Chemotherapy Versus ChemotherapyOncologyPathologyPleural DiseaseCancer Treatment	2023	86

Page 1